Erratum: The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [Ann Oncol, 28, 9, (2017) (2256-2263)] DOI: 10.1093/annonc/mdx305

P. N. Aguiar, L. A. Perry, J. Penny-Dimri, H. Babiker, H. Tadokoro, R. A. de Mello, G. L. Lopes

Research output: Contribution to journalComment / DebateOtherpeer-review

6 Citations (Scopus)


This article has been corrected to add affiliation information and to amend the caption for Figure 6A and B.

Original languageEnglish
Pages (from-to)1078
Number of pages1
JournalAnnals of Oncology
Issue number4
Publication statusPublished - 1 Apr 2018

Cite this